Michael Houghton

Director, Li Ka Shing Applied Virology Institut/ Professor

University of Alberta

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Michael Houghton is the Director of the Li Ka Shing Applied Virology Institute at the University of Alberta, Canada. His research focuses on the development of antiviral therapies, hepatitis C vaccine research, and the study of viral infections, including COVID-19 and human cytomegalovirus. He has authored several recent articles exploring novel therapeutic approaches and the molecular dynamics of virus-host interactions.

Articles (10)

Year:

2025

Year:

2025

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

James A. Nieman

University of Alberta

CANADA

View details

Deanna Santer

Assistant Professor and GSK Chair in Immunology of Infectious Diseases

University of Manitoba

CANADA

View details

Harley Kurata

Associate Professor

University of Alberta

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Houghton

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A rat hepacivirus model to aid hepatitis C viral vaccine development?

Discovery of Novel Pyrido[2,3‐b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition

Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19.

A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis

SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1

A structure-based computational workflow to predict liability and binding modes of small molecules to hERG.

Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.

Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase

Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells

Seroepidemiology of hepatitis C among drug users at a detoxification center in Southeast China

Collaborators (3)

James A. Nieman

Deanna Santer

Harley Kurata

Make your next move.